Pozen (POZN +3.9%) gains after saying it's sold most of the future royalty and milestone...


Pozen (POZN +3.9%) gains after saying it's sold most of the future royalty and milestone payments under its licensing agreement with Glaxo Group covering Treximet sales in the United States, to a financial investor for $75M.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs